HRT for Perimenopause: When to Start and What to Expect

Perimenopause is the stage before menopause — the transition leading up to it.

FDA puts the average age of menopause in the US at 51, and the label language for menopausal hormone products is written about menopause: products such as Premarin (conjugated estrogens) tablets are indicated for moderate-to-severe hot flashes (vasomotor symptoms) and moderate-to-severe vulvar and vaginal atrophy due to menopause, among other uses.

The Menopause Society's 2022 position statement is also written about menopause — its favorable window for hormone therapy covers women younger than 60 or within 10 years of menopause onset — and calls hormone therapy the most effective treatment for hot flashes (vasomotor symptoms) and genitourinary syndrome of menopause.

What the sources we reviewed do not contain is perimenopause-specific guidance: beyond that general timing framework, no HRT guidance written for the transition itself was located, and the FDA indications say "due to menopause." That gap is why this page stays close to what the labels and the 2022 statement actually say.

The clearest signal is FDA's November 2025 labeling request.

On November 10, 2025, FDA announced it was initiating removal of boxed-warning language on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels — and, in the same request, asked that systemic product labels add consideration of starting hormone therapy for moderate-to-severe hot flashes in women under 60 or within 10 years of menopause.

The Menopause Society's 2022 statement describes the same window from the evidence side: for women younger than 60 or within 10 years of menopause onset who have no contraindications, the benefit-risk ratio is favorable for treating bothersome hot flashes and preventing bone loss.

Starting more than 10 years after menopause or after age 60 is less favorable, the statement says, because the absolute risks of heart disease, stroke, blood clots and dementia are higher.

Both documents set the window by age (under 60) or by time since menopause (within 10 years), and both were written about hormone therapy for menopause — which is the awkward part for a premenopausal reader.

As far as our research shows, neither addresses starting during the transition directly, the label indications are for symptoms due to menopause, and our research found no perimenopause-specific guidance beyond this framework.

Whether HRT makes sense for you during perimenopause is a decision for you and a licensed clinician with your full history, not something a page can settle.

The labeled indications set the menu.

FDA-approved menopausal hormone products such as Premarin tablets are indicated for moderate-to-severe hot flashes, moderate-to-severe vulvar and vaginal atrophy due to menopause, and prevention of postmenopausal osteoporosis, among other uses — and the indications we reviewed do not include energy, libido, weight loss or "anti-aging."

Within that menu, the distinctions the sources actually use are these.

FDA's 2025 labeling request refers to "systemic" products as a group, and systemic estrogen-alone products keep a boxed warning for endometrial cancer.

Risk depends on whether a progestogen is used, alongside the type, dose, duration and route of therapy and the timing of initiation, per the Menopause Society.

And when the problem is vaginal or genitourinary symptoms alone, the 2022 statement recommends low-dose vaginal estrogen or other local therapies — vaginal DHEA, oral ospemifene — when over-the-counter products are not enough and systemic therapy is not otherwise indicated.

One marketing term to keep straight: "bioidentical" is not the same as "compounded." FDA has approved many estradiol, progesterone and testosterone products that are reviewed for safety and efficacy, while compounded "BHRT" blends are not FDA-reviewed.

Our hormone replacement therapy guide covers the forms, the pellet question and the compounded market in depth.

The risk evidence the labels themselves cite is the Women's Health Initiative (WHI).

WHI randomized 27,347 postmenopausal women aged 50 to 79 (mean age 63) in 1993-1998 to estrogen plus progestin or estrogen alone versus placebo.

FDA says the estrogen-plus-progestin trial was stopped in 2002 after an increased risk of breast cancer was reported, and the estrogen-alone trial in 2004 for increased stroke risk and no heart-disease prevention.

The participants averaged 63 years old; the average age of menopause in the US is 51.

An 18-year follow-up published in JAMA in 2017 found no association with all-cause, cardiovascular or cancer mortality.

The label changes roll out product by product.

Premarin's DailyMed label effective June 4, 2026, for example, still carried a boxed warning for endometrial cancer, cardiovascular disorders, breast cancer and probable dementia.

The labels also name who should not take estrogen products.

Estrogen labels such as Premarin's list contraindications including undiagnosed abnormal genital bleeding, current or past breast cancer (except selected metastatic cases), estrogen-dependent cancers, current or past blood clots (DVT/PE), stroke or heart attack, liver disease, and inherited clotting disorders.

Screening for those conditions is a medical-history job, which is why the prescriber matters more than the marketing.

If you are considering HRT through a med spa or wellness clinic, the heart of the arrangement is the prescription.

Our research did not find a federal rule naming who may prescribe HRT at a med spa or wellness clinic; who may prescribe — a physician (MD or DO), a nurse practitioner (NP) or a physician associate/assistant (PA) — and under what supervision is a state-law question.

Ask any clinic directly which clinician writes the prescription and how supervision works.

Our guide to how to choose a med spa covers credentials, review-reading, consultation standards and the questions worth asking before you pay.

And nothing on this page is a recommendation for or against HRT: the timing framework, the labeled indications and the risks above are the material to bring into a conversation with a licensed clinician who can evaluate your own case.